1. Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.
- Author
-
Sameshima A, Wada T, Ito T, Kashimura A, Sawakawa K, Yonezawa R, Tsuneki H, Ishii Y, Sasahara M, Saito S, and Sasaoka T
- Subjects
- Animals, Behavior, Animal drug effects, Body Temperature Regulation drug effects, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 immunology, Diabetes Mellitus, Type 2 metabolism, Diet, High-Fat adverse effects, Energy Metabolism drug effects, Female, Intra-Abdominal Fat drug effects, Intra-Abdominal Fat immunology, Intra-Abdominal Fat metabolism, Liver drug effects, Liver immunology, Liver metabolism, Macrophages drug effects, Macrophages immunology, Macrophages metabolism, Mice, Inbred C57BL, Motor Activity drug effects, Non-alcoholic Fatty Liver Disease etiology, Non-alcoholic Fatty Liver Disease prevention & control, Obesity, Abdominal etiology, Obesity, Abdominal physiopathology, Ovariectomy, Panniculitis etiology, Aging, Diabetes Mellitus, Type 2 drug therapy, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Disease Models, Animal, Obesity, Abdominal complications, Panniculitis prevention & control, Pyrazoles therapeutic use, Thiazolidines therapeutic use
- Abstract
A decrease in serum estrogen levels in menopause is closely associated with the development of visceral obesity and the onset of type 2 diabetes in women. In the present study, we demonstrated the therapeutic effects of the novel DPP4 inhibitor, teneligliptin, on the features of postmenopausal obesity in mice. In the control group, female C57BL/6 mice were sham-operated and maintained on a standard diet. In the postmenopausal obese group, ovariectomized (OVX) mice were maintained on a high-fat diet, and were referred to as OVX-HF. In the treated group, teneligliptin at 60 mg/kg per day was administrated to OVX-HF, and were referred to as Tene. After a 12-week food challenge, the metabolic phenotypes of these mice were analyzed. Body weight, fat accumulation, and glucose intolerance were greater in OVX-HF than in control, while these abnormalities were markedly improved without alterations in calorie intake in Tene. Teneligliptin effectively ameliorated the characteristics of metabolic abnormalities associated with postmenopausal obesity. Regarding chronic inflammation in visceral adipose tissue, the numbers of F4/80(+)CD11c(+)CD206(-) M1-macrophages in flow cytometry, crown-like structure formation in immunohistochemistry, and proinflammatory cytokine expression were significantly attenuated in Tene. Hepatic steatosis was also markedly improved. Furthermore, decreased energy consumption in the dark and light phases, reduced locomotor activity in the dark phase, and lowered core body temperature in OVX-HF were ameliorated in Tene. Since obesity and reduced energy metabolism are a common physiology of menopause, teneligliptin appears to be beneficial as a treatment for type 2 diabetes in postmenopausal obesity., (© 2015 Society for Endocrinology.)
- Published
- 2015
- Full Text
- View/download PDF